Abstract
BackgroundCirculating tumor cells (CTCs) play an important role in progression and metastasis, particularly in form of cluster, which is called circulating tumor microemboli (CTM), and can be found in the peripheral blood of cancer patients. The aim of this study was to evaluate the presence of CTCs and CTM, and its influence on tumor progression in lung cancer patients.MethodsCTCs were isolated by Isolation by Size of Epithelial Tumor cells (ISET®) Technology. The samples of metastatic lung cancer patients were collected before the beginning of systemic chemotherapy. CTCs and CTM were identified according to their morphological features.ResultsFifteen patients were analyzed. Patients who had CTM in blood previously the beginning of systemic therapy had poor progression-free survival (PFS) compared to those with absence of CTM, although without statistical significance (median PFS 3.1 months × 6.7 months, p = 0.29). Moreover, patients without any prior treatment had less than 3 CTCs/mL compared to patients previously exposed to chemotherapy, who had 3 CTCs/mL or more (p = 0.31). Additionally, these patients, with prior treatment, showed poor PFS, compared to chemo-naive patients, although without statistical significance (mean PFS: 4.6 months × 7.3 months, p = 0.47).ConclusionsWe identified, even in a limited number of samples, that an elevated baseline levels of CTCs and the presence of CTM were associated with poor prognosis in patients with metastatic lung cancer. In addition, we showed that an increase of CTCs counts could indicate a pre-existing resistance. However, further studies with a large cohort are needed to support this information.
Highlights
Circulating tumor cells (CTCs) play an important role in progression and metastasis, in form of cluster, which is called circulating tumor microemboli (CTM), and can be found in the peripheral blood of cancer patients
Circulating tumor cells (CTCs) are rare cells coming from the primary tumor or metastatic site that can be detached and, invade blood circulation, and are known to play an important role in metastasis process [4]
CTCs can pass through a series of alterations, such as epithelial-mesenchymal transition (EMT), a well-known conformational change that permit the invasion to blood vessels as well as overflow to distant sites [5]
Summary
Circulating tumor cells (CTCs) play an important role in progression and metastasis, in form of cluster, which is called circulating tumor microemboli (CTM), and can be found in the peripheral blood of cancer patients. Lung cancer is a public health issue, representing the most frequently diagnosed and with higher mortality rate in men and the second in women, being responsible for about 1.59 million deaths in the world [1]. Circulating tumor cells (CTCs) are rare cells coming from the primary tumor or metastatic site that can be detached and, invade blood circulation, and are known to play an important role in metastasis process [4]. These cells have specific intrinsic features of invasion and survival in blood circulation. CTC analysis has been shown to be a good marker for evaluation of tumor
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
